Compare Coinbase Global, Inc. (COIN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Viatris Inc — how do they compare? Coinbase Global, Inc. trades at $182.07 (market cap $45.38B), while Viatris Inc trades at $17.58 (market cap $20.03B). The key difference: Coinbase Global, Inc. is far larger — about 2.3× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Viatris Inc for 57 Days on average.
| COIN | VTRS | |
|---|---|---|
Market Cap | $45.38B | $20.03B |
Volume | 11,013,940 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $387.00 | $18.27 |
52-Week Low | $141.09 | $9.74 |
Typical Hold Time | 78 Days | 57 Days |
Enterprise Value | $43.03B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coinbase Global (COIN) trades at $181.09, up 1.48% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported $7.18B revenue in 2025 with $1.26B net income, though recent quarterly earnings have missed expectations. Positive developments include CFTC approval for derivatives clearing and expanded partnerships with Citigroup, while analyst consensus remains bullish with a $211.91 price target.
The stock presents growth potential from expanding derivatives business and institutional partnerships, but faces risks from earnings volatility and crypto market exposure. With 55% analyst buy ratings and strong cash flow generation, COIN offers upside to price targets, though investors should monitor execution on profitability goals amid competitive pressures.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
